Mwanzo688235 • SHA
add
Beigene Ltd
Bei iliyotangulia
¥ 230.20
Bei za siku
¥ 214.55 - ¥ 231.37
Bei za mwaka
¥ 111.22 - ¥ 248.00
Thamani ya kampuni katika soko
185.35B CNY
Wastani wa hisa zilizouzwa
2.32M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
SHA
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 1.19B | 84.84% |
Matumizi ya uendeshaji wa biashara | 1.09B | 19.51% |
Mapato halisi | -139.70M | 58.27% |
Kiwango cha faida halisi | -11.75 | 77.43% |
Mapato kwa kila hisa | -0.80 | -196.59% |
EBITDA | -33.25M | 90.73% |
Asilimia ya kodi ya mapato | -112.84% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 2.63B | -17.16% |
Jumla ya mali | 5.92B | 1.99% |
Jumla ya dhima | 2.59B | 14.14% |
Jumla ya hisa | 3.33B | — |
hisa zilizosalia | 106.72M | — |
Uwiano wa bei na thamani | 7.37 | — |
Faida inayotokana na mali | -3.26% | — |
Faida inayotokana mtaji | -4.29% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -139.70M | 58.27% |
Pesa kutokana na shughuli | 111.61M | 128.21% |
Pesa kutokana na uwekezaji | -247.31M | 26.86% |
Pesa kutokana na ufadhili | 30.05M | -92.11% |
Mabadiliko halisi ya pesa taslimu | -155.64M | 57.59% |
Mtiririko huru wa pesa | 434.97M | 505.95% |
Kuhusu
BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has offices in North America, Europe, South America, Asia and Australia. BeiGene has a large presence in the Chinese market. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November, 2024 the company announced its intention to rebrand as BeOne Medicines. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
28 Okt 2010
Tovuti
Wafanyakazi
11,000
